Futile: Prostate Cancer Vaccine Phase 3 Trial Ends Futile: Prostate Cancer Vaccine Phase 3 Trial Ends
Prostvac is an immunotherapy designed to induce T-cell responses and thus kill prostate cancer cells. As a monotherapy, it is not effective.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Health | Hematology | Immunotherapy | Prostate Cancer | Vaccines